2026年6月17日 7:27 ET 发布 · 更新于 5 个月前 · 1 个来源
UniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy
bloomberg
·
原始报道
INFERY
UniQure NV shares soared after the company announced it will be able to seek US approval for its Huntington’s disease gene therapy before conducting a new study, a dramatic reversal that shows the Trump administration is relaxing its previous hard-line stance on drug reviews.
原文